Xenon Pharmaceuticals
Dokainish & Company
Bank of China
Dokainish & Company
Münchener Rückversicherungs-Gesellschaft
lululemon
Ottawa-Carleton District School Board (OCDSB)
Connect with headhunters to apply for similar jobsHSB Canada
Kingston Health Sciences Centre
Winnipeg Regional Health Authority (WRHA)
Xenon Pharmaceuticals
Roots To Grow
Harvard
Pembina Pipeline Corp.
Brock University
Infrastructure Engineering, Inc.
Broccolini
Government of Nova Scotia
University of Colorado
Family Services of Greater Vancouver
Senior Living Residences
Warner Bros. Entertainment
A biopharmaceutical company in Vancouver is seeking a Principal/Senior Principal Scientist, CMC, Analytical Chemistry. The role involves developing analytical methodologies and providing support for drug development. Ideal candidates will have a Ph.D. in Analytical Chemistry and at least 10 years of relevant experience, with expertise in techniques such as HPLC and NMR. This position offers competitive benefits, including a robust Total Rewards program and support for relocation if needed.
Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience‑focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life‑changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late‑stage clinical development for multiple indications. Building upon the positive results and compelling data from our Phase 2b X‑TOLE study in adult patients with focal epilepsy, our Phase 3 epilepsy program includes multiple clinical trials evaluating azetukalner in patients with focal onset seizures and primary generalized tonic‑clonic seizures. In November 2025, we announced the completion of patient enrollment in our Phase 3 X‑TOLE2 study, and topline data are anticipated in March 2026. We also have multiple Phase 3 azetukalner clinical trials in major depressive disorder (MDD) and bipolar depression (BPD) underway, based on topline data from our Phase 2 X‑NOVA clinical trial. In addition, we are proud of the leading‑edge science coming out of our discovery labs, including early‑stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. We have recently initiated Phase 1 studies for our follow‑on Kv7 channel opener, XEN1120, and our lead Nav1.7 development candidate, XEN1701, in pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
We are seeking a Principal/Senior Principal Scientist, CMC, Analytical Chemistry to join our team. This position will report to the Executive Director, CMC, Analytical Development and will be responsible for the development of analytical methodology and characterization activities in support of new drug substance and new drug product development and manufacturing. He/she will provide analytical support for API and drug product manufacture in support of preclinical and clinical batches.
This position will be based out of Vancouver, BC, Canada. The level of the position will be commensurate with the candidate’s education and industry experience. Relocation and immigration support will be provided, if required. Hybrid positions require a minimum of two onsite days per week. On‑site positions require up to five on‑site days per week.
Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short‑ and long‑term disability, accidental death & dismemberment, and life insurance programs, Employee Assistance Program, travel insurance, and retirement savings programs with company matching contributions.
Xenon encourages time to rest and re‑charge through vacation, personal days, sick days, and an end‑of‑year company shutdown. Xenon highly values employee development and has an expanding Training, Learning & Development program, including a Tuition Assistance program for advanced degrees.
* The salary benchmark is based on the target salaries of market leaders in their relevant sectors. It is intended to serve as a guide to help Premium Members assess open positions and to help in salary negotiations. The salary benchmark is not provided directly by the company, which could be significantly higher or lower.